Epigenomics AG

Headquarters: Berlin, Germany

Employees: 32

CEO: Mr. Gregory Hamilton

Market Cap

€6.2 Million

EUR as of Feb. 1, 2023

US$6.7 Million

Market Cap History

Epigenomics AG market capitalization over time

Evolution of Epigenomics AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Epigenomics AG

Detailed Description

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Top 1-year algo backtest: +313.24%

$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Epigenomics AG has the following listings and related stock indices.

Stock: FSX: ECX wb_incandescent

Stock: XETR: ECX wb_incandescent

Stock: OTC: EPGNF wb_incandescent

Stock: OTC: EPGNY wb_incandescent



Geneststrasse 5

Berlin, 10829


Phone: 49 30 243 450

Fax: 49 30 2434 5555